B
Benjamin Weide
Researcher at University of Tübingen
Publications - 132
Citations - 10305
Benjamin Weide is an academic researcher from University of Tübingen. The author has contributed to research in topics: Melanoma & Antigen. The author has an hindex of 39, co-authored 129 publications receiving 7891 citations. Previous affiliations of Benjamin Weide include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
Diana Meckbach,Ulrike Keim,Sabina Richter,Ulrike Leiter,Thomas Eigentler,Jürgen Bauer,Annette Pflugfelder,Petra Büttner,Claus Garbe,Benjamin Weide +9 more
TL;DR: No differences in prognosis were observed according to the BRAF mutational status in patients with distant metastasis treated with monochemotherapy, and no differences in overall survival were detected.
Journal ArticleDOI
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
TL;DR: Different classes of immunologic correlates such as pharmacodynamic changes observed in all treated patients, correlates with response during treatment or at the time-point of tumor assessment, as well as predictive markers for response and for immune-related adverse events are described.
Journal ArticleDOI
Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
Ferdinand Seith,Andrea Forschner,Benjamin Weide,B. Gückel,Martin Schwartz,Johannes Schwenck,Johannes Schwenck,Ahmed E. Othman,Matthias Fenchel,Claus Garbe,Konstantin Nikolaou,Nina F. Schwenzer,Christian la Fougère,Christina Pfannenberg +13 more
TL;DR: It is indicated that an effective systemic immune response in patients undergoing CIT can be detected as a significantly increased spleen activity in 18F-FDG-PET as early as 2 weeks after treatment initiation.
Journal ArticleDOI
CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.
Pia S. Zeiner,Jenny Zinke,D. J. Kowalewski,Simon Bernatz,Julia Tichy,Michael W. Ronellenfitsch,Frits Thorsen,Annemarie Berger,Marie-Therese Forster,Arnaud Muller,Joachim P. Steinbach,Joachim P. Steinbach,Rudi Beschorner,J Wischhusen,Hans-Michael Kvasnicka,Karl-Heinz Plate,Karl-Heinz Plate,S. Stefanović,Benjamin Weide,Michael Mittelbronn,Patrick N. Harter,Patrick N. Harter +21 more
TL;DR: It is demonstrated that a functional HLA class II processing machinery in brain metastatic tumor cells, reflected by a high expression of CD74 and a complex tumor cell HLA peptidome, seems to be crucial for better patient prognosis.
Journal ArticleDOI
S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Sail Nawaf Rashid Abusaif,Zeinab Jradi,Laura Held,Annette Pflugfelder,Benjamin Weide,Friedegund Meier,Claus Garbe,Thomas Eigentler +7 more
TL;DR: Measurement of S100B and LDH levels during treatment with vemurafenib indicates an initial response; however, this does not seem to be sufficient in detecting tumor progression and is thus not an alternative to monitoring with imaging examinations.